Drugs News and Research

RSS

Researchers identify experimental drugs to block treatment-resistant leukemia

Research in mice and human cell lines has identified an experimental compound dubbed TTT-3002 as potentially one of the most potent drugs available to block genetic mutations in cancer cells blamed for some forms of treatment-resistant leukemia.

9 Apr 2014

Abnormal levels of lipid molecules can trigger autism during prenatal brain development

In a groundbreaking York University study, researchers have found that abnormal levels of lipid molecules in the brain can affect the interaction between two key neural pathways in early prenatal brain development, which can trigger autism.

9 Apr 2014

New data sharing platform to advance cancer research: an interview with Dr. Charles Hugh-Jones, Chief Medical Officer, Sanofi U.S.

Project Data Sphere, LLC (PDS) is an independent, not-for-profit initiative of the CEO Roundtable on Cancer’s Life Sciences Consortium (LSC), a group formed by President Bush in 2001 to look at the ways in which different organisations can come together to improve outcomes in cancer research that no individual group could do by itself. The data-sharing platform is one of the projects developed by the group.

From Sanofi 8 Apr 2014

Ambit initiates QUANTUM-R Phase 3 clinical trial of quizartinib in FLT3-ITD positive AML patients

Ambit Biosciences, a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced the initiation of the QUANTUM-R Phase 3 clinical trial comparing quizartinib as monotherapy to chemotherapy regimens in relapsed/refractory acute myeloid leukemia (AML) patients with the FMS-like tyrosine kinase-3 (FLT3)-ITD mutation.

8 Apr 2014

Curis and Debiopharm present data for Debio 0932 at Annual Meeting of AACR

Curis, Inc., an oncology focused company developing novel, targeted drug candidates for the treatment of human cancers, and Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology as well as companion diagnostics, today announced presentation of data for Debio 0932 at the Annual Meeting of the American Association for Cancer Research (AACR) that demonstrated synergy between Debio 0932 and various standard of care (SOC) agents in multiple in vitro and xenograft models of non-small cell lung cancer (NSCLC) and renal cell carcinoma (RCC).

8 Apr 2014

USPTO grants patent for low-cost dry powder inhaler to Hovione

Hovione announced today that the United States Patent and Trademark Office (USPTO) has granted a patent for a capsule-based, low-cost dry powder inhaler (DPI) to Hovione. This happened less than three years after the patent was filed and after just one Office Action - unusual speed for an inhaler application.

8 Apr 2014

I-SPY 2 trial qualifies neratinib for HER2-positive breast cancer

In an innovative clinical trial led by UC San Francisco, the experimental drug neratinib along with standard chemotherapy was found to be a beneficial treatment for some women with newly diagnosed, high-risk breast cancer.

8 Apr 2014

Research to understand exactly how bleach kills bacteria

Spring cleaning often involves chlorine bleach, which has been used as a disinfectant for hundreds of years. But our bodies have been using bleach's active component, hypochlorous acid, to help clean house for millennia. As part of our natural response to infection, certain types of immune cells produce hypochlorous acid to help kill invading microbes, including bacteria.

8 Apr 2014

TSRI reveals new aspects of more potent anti-diabetic drugs with fewer serious side effects

8 Apr 2014

Pradaxa receives FDA approval for treatment and reduction of risk of recurrence of DVT and PE

Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Pradaxa® (dabigatran etexilate mesylate) for the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in patients who have been treated with a parenteral anticoagulant for five to 10 days, and to reduce the risk of recurrent DVT and PE in patients who have been previously treated. DVT and PE are collectively referred to as venous thromboembolism (VTE).

8 Apr 2014

NRAS gene that plays fundamental role in cancer development produces five gene variants, says study

A new study shows that a gene discovered 30 years ago and now known to play a fundamental role in cancer development produces five different gene variants (called isoforms), rather than just the one original form, as thought.

8 Apr 2014

Added benefit of antiviral drug combination in treatment of HIV-1 patients is not proven

The German Institute for Quality and Efficiency in Health Care (IQWiG) reassessed the antiviral drug combination rilpivirine/emtricitabine/tenofovir. In early 2012, the combination was approved for the treatment of adults infected with human immunodeficiency virus type 1 (HIV-1) who have not received previous antiretroviral treatment.

8 Apr 2014

Eli Lilly presents early-stage data from several targeted cancer therapies at AACR 2014

Eli Lilly and Company will present early-stage data from several targeted cancer therapies – including bemaciclib "beh meh sye' klib" (LY2835219), its oral, cell-cycle inhibitor of CDK4/6 – that make up its diverse clinical oncology pipeline during the American Association for Cancer Research (AACR) Annual Meeting 2014 held in San Diego, Calif. from April 5 – 9.

7 Apr 2014

Findings could lead to more potent anti-diabetic drugs with fewer side effects

Scientists thought they basically knew how the most common drugs used to treat type 2 diabetes worked, but a new study from the Florida campus of The Scripps Research Institute (TSRI) reveals unexpected new aspects of the process. These findings could eventually lead to more potent anti-diabetic drugs with fewer serious side effects.

7 Apr 2014

6 months of hormonal treatment in addition to radiotherapy improves outcome for prostate cancer

Vienna, Austria: Men with prostate cancer that is small and confined to the prostate gland but that is at risk of growing and spreading, do better if they are treated with radiotherapy combined with androgen deprivation therapy, which lowers their levels of the male hormone, testosterone, according to new research.

7 Apr 2014

Ambit initiates Phase 2 study of quizartinib in acute myeloid leukemia patients

Ambit Biosciences, a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced the initiation of the Phase 2 cohort of the MD Anderson Cancer Center-sponsored Phase 1/2 study of quizartinib in combination with either 5-azacitidine or low dose cytarabine for previously untreated FLT3-ITD positive acute myeloid leukemia (AML) patients age 60 or older, or FLT3-ITD positive AML patients 18 years of age or older in first relapse.

7 Apr 2014

Researchers demonstrate power of Droplet Digital PCR at 2014 AACR annual meeting

Helping doctors monitor their melanoma patients' progress in response to treatment is just one of the many exciting applications of Bio-Rad's Droplet Digital PCR (ddPCR-) technology being showcased at the 2014 American Association for Cancer Research (AACR) Annual Meeting taking place in San Diego, CA from April 5-9.

7 Apr 2014

Caffeine has positive effect on tau deposits in Alzheimer's disease

As part of a German-French research project, a team led by Dr. Christa E. Müller from the University of Bonn and Dr. David Blum from the University of Lille was able to demonstrate for the first time that caffeine has a positive effect on tau deposits in Alzheimer's disease.

7 Apr 2014

Research roundup: Mental health parity; nurses' workload; can restaurants reduce portion size?

Historically, health insurance covered mental health care differently than other medical care. Recent laws have begun bringing them into balance. ... Congress passed the Mental Health Parity and Addiction Equity Act (MHPAEA) in 2008. ... the MHPAEA applied to large group health plans, both fully and self-insured, and included a cost exemption.

7 Apr 2014

Deciphera Pharmaceuticals initiates Phase 1 clinical trial of pan-RAF inhibitor LY3009120

...

7 Apr 2014

Drugs News and Research

Researchers identify experimental drugs to block treatment-resistant leukemia

Abnormal levels of lipid molecules can trigger autism during prenatal brain development

New data sharing platform to advance cancer research: an interview with Dr. Charles Hugh-Jones, Chief Medical Officer, Sanofi U.S.

Ambit initiates QUANTUM-R Phase 3 clinical trial of quizartinib in FLT3-ITD positive AML patients

Curis and Debiopharm present data for Debio 0932 at Annual Meeting of AACR

USPTO grants patent for low-cost dry powder inhaler to Hovione

I-SPY 2 trial qualifies neratinib for HER2-positive breast cancer

Research to understand exactly how bleach kills bacteria

TSRI reveals new aspects of more potent anti-diabetic drugs with fewer serious side effects

Pradaxa receives FDA approval for treatment and reduction of risk of recurrence of DVT and PE

NRAS gene that plays fundamental role in cancer development produces five gene variants, says study

Added benefit of antiviral drug combination in treatment of HIV-1 patients is not proven

Eli Lilly presents early-stage data from several targeted cancer therapies at AACR 2014

Findings could lead to more potent anti-diabetic drugs with fewer side effects

6 months of hormonal treatment in addition to radiotherapy improves outcome for prostate cancer

Ambit initiates Phase 2 study of quizartinib in acute myeloid leukemia patients

Researchers demonstrate power of Droplet Digital PCR at 2014 AACR annual meeting

Caffeine has positive effect on tau deposits in Alzheimer's disease

Research roundup: Mental health parity; nurses' workload; can restaurants reduce portion size?

Deciphera Pharmaceuticals initiates Phase 1 clinical trial of pan-RAF inhibitor LY3009120

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News